Amicus Therapeutics Inc [NASDAQ: FOLD] price plunged by -3.50 percent to reach at -$0.32.
The one-year FOLD stock forecast points to a potential upside of 48.06. The average equity rating for FOLD stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $16.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 06, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $18, while Wells Fargo analysts kept a Overweight rating on FOLD stock.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.29, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 5.05. The Price to Book ratio for the last quarter was 13.39, with the Price to Cash per share for the same quarter was set at 0.81.
FOLD Stock Performance Analysis:
Amicus Therapeutics Inc [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.71. With this latest performance, FOLD shares dropped by -5.44% in over the last four-week period, additionally sinking by -21.00% over the last 6 months – not to mention a drop of -27.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 39.42, with the RSI for the last a single of trading hit 37.06, and the three-weeks RSI is set at 40.72 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 9.32, while it was recorded at 8.99 for the last single week of trading, and 10.23 for the last 200 days.
Insight into Amicus Therapeutics Inc Fundamentals:
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 3.39.
Amicus Therapeutics Inc [FOLD] Institutonal Ownership Details
There are presently around $100.63%, or 101.46%% of FOLD stock, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 28.59 million shares, which is approximately 9.4382%. PERCEPTIVE ADVISORS LLC, holding 28.06 million shares of the stock with an approximate value of $$278.33 million in FOLD stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$271.81 million in FOLD stock with ownership which is approximately 9.0199%.
